Novartis AG ADR (NVS)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
NVS
Novartis AG ADR
$150.47
-0.50%
HEALTHCARE · Cap: $302.86B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$3.38
+1.20%
HEALTHCARE · Cap: $628.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 290716% more annual revenue ($57.36B vs $19.73M). NVS leads profitability with a 17.5% profit margin vs 6.0%. ZJYL trades at a lower P/E of 20.8x. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
ZJYL
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-56.8%
Fair Value
$95.95
Current Price
$150.47
$54.52 premium
Intrinsic value data unavailable for ZJYL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.7% revenue growth
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 3.4% — below average capital efficiency
6.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bull Case : ZJYL
The strongest argument for ZJYL centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
ZJYL carries more volatility with a beta of 7.32 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 15/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?